IMPACT: Pemvidutide Phase 2 trial (NCT05989711)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 212
- actual
- Start
- 27 Jul 2023 (actual)
- Primary completion
- 25 Nov 2025 (actual)
- Sponsor
- Altimmune, Inc.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Pemvidutide 1.2 mg | Experimental | Drug: Pemvidutide | Not stated |
| Pemvidutide 1.8 mg | Experimental | Drug: Pemvidutide | Not stated |
| Placebo | Placebo comparator | Drug: Placebo | Not stated |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis | 24 weeks |
| Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) | 24 weeks |
| Incidence of Treatment Emergent Adverse Events | 52 weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving the composite of both NASH resolution and at least 1 stage improvement of liver fibrosis at 24 weeks | 24 weeks |
| Relative change (%) in liver fat content by MRI-PDFF | 24 weeks and 48 weeks |
| Absolute change in MRI-based corrected T1 (cT1) imaging | 24 weeks and 48 weeks |
| Absolute change in alanine aminotransferase (ALT) | 24 weeks and 48 weeks |
| Absolute change in Enhanced Liver Fibrosis (ELF) score | 24 weeks and 48 weeks |
| Absolute change in Fibroscan-AST (FAST) score | 24 weeks and 48 weeks |
| Relative (%) change in body weight | 24 weeks and 48 weeks |
| Absolute changes in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) | 24 weeks and 48 weeks |
| Change in HbA1c (%) | 24 weeks and 48 weeks |
| Change in glucose (mg/dL) | 24 weeks and 48 weeks |
| Change in systolic and diastolic blood pressure (mmHg) | 24 weeks and 48 weeks |
| Change in heart rate (beats per minute) | 24 weeks and 48 weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.